



**GOVERNMENT OF PAKISTAN
THE PATENT OFFICE**

No.2/2/2003-F.Sec.

Dated: 24-10-2005

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEK-ENDING 20-08-2005 TO BE PUBLISHED ON 25-10-2005
IN THE GAZETTE OF PAKISTAN PAT-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Ph: 9215488



**GOVERNMENT OF PAKISTAN
THE PATENT OFFICE**

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

15-8-2005

750/2005	Pharmacia Corporation, USA (Priority 20-11-2002 USA) Divisional	“ N-terminally monopegylated human growth hormone conjugates and process for their preparation”
751/2005	Wyeth USA (Priority 16-08-04 USA)	“ 4-(2, 4-dichloro-5-methoxyphenyl)amin o-6-methoxy-7- {[5-(substituted-am ino) methyl]-3-quinolinecarbonitriles as kinase inhibitors”
752/2005	Theravance, Inc., USA (Priority 16-08-04 USA0)	“Crystalline form of a biphenyl compound”
753/2005	TELENOR ASA, Norway (Priority 16-08-04 USA)	“ A method, system, and computer program product for ranking of documents using link analysis, with remedies for sinks “
754/2005	Glaxo Group Limited Great Britain (Priority 16-08-04 GB)	“Novel compounds”
755/2005	Aventis Pharma Deutschland GmbH Germany	“ Aryl-substituted polycyclic amines, process for their



GOVERNMENT OF PAKISTAN
THE PATENT OFFICE

	(Priority 16-08-04 Germany)	preparation and their use as medicaments”
756/2005	Aventis Pharma Deutschland GmbH Germany (Priority 16-08-04 Germany)	“ Aryl-substituted polycyclic amines, process for their preparation and their use as medicaments”
	<u>16-8-2005</u>	
757/2005	Sanofi-aventis France (Priority 19-08-04 France)	“Pharmaceutical composition in the form of a gastric retention tablet containing an active ingredient”
758/2005	Novartis AG Switzerland (Priority 17-08-04 GB)	“Compounds and compositions useful as cathepsin s inhibitors”
759/2005	Pfizer Inc. USA (Priority 18-08-04 USA)	“Inhibitors of hepattis C virus rna-dependent rna polymerase, and composition and treatment using the same”
760/2005	H. Lundbeck A/S Denmark (Priority 27-12-02 DK)	“ 1, 2, 4-triaminobenzene derivatives “
761/2005	Janssen Pharmaceutica N.V., Belgium (Priority 16-08-04 US)	“ Use of tpo mimetic compounds and pharmaceutical compositions in the treatment of anemia “
	<u>17-08-2005</u>	
762/2005	Bombardier Transportation GmbH, Germany (Priority 24-08-04 Germany)	“ Bogie for rail vehicles “
763/2005	AstraZeneca AB Sweden (Priority 28-08-04 GB)	“ Compounds “



GOVERNMENT OF PAKISTAN
THE PATENT OFFICE

<u>18-8-2005</u>		
764/2005	Aventis Pharmaceuticals Inc, USA (Priority 19-8-04 USA)	“ Substituted thienopyrrole carboxylic acid amides, pyrrolothazole carboxylic acid amides, and related analogs as inhibitors of casein kinase Ie”
765/2005	Aventis Pharmaceuticals Inc, USA (Priority 19-8-04 USA)	“ 3-substituted-5-and-6-aminolalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase Ie”
766/2005	Merck Sharp & Dhome Limited, United Kingdom (Priority 27-08-04 GB)	“ Arylsulphonylstilbene derivatives for treatment of insomnia and related conditions ”
767/2005	Unilever Plc, England (Priority 26-10-04 USA)	“ Mild acyl isethionate toilet bar composition “
768/2005	Wyeth, USA (Priority 19-08-04 USA)	“Process for the synthesis C-2, C-3 substituted N-alkylated indoles useful as CPLA2 inhibitors”
769/2005	Wyeth, USA (Priority 20-08-04 USA)	“ Rapamycin polymorph II and uses thereof “
<u>19-08-2005</u>		
770/2005	DyStar Textilfarben GmbH & Co. Deutschland KG, Germany (Priority 21-08-04 Germany)	“ Novel quinoneimine sulfur dye compositions, production thereof and use for dyeing cellulosic material”
771/2005	Recordati Ireland Limited, Ireland (Priority 24-08-04 USA)	“Lercanidipine salts”

20-08-2005



GOVERNMENT OF PAKISTAN
THE PATENT OFFICE

772/2005	1. Prometic Biosciences Ltd. British Isles 2. American National Red Cross, USA (Priority 20-08-04 USA)	“Sequential protein isolation and purification schemes by affinity chromatography”
773/2005	AstraZeneca AB, Sweden (Priority 31-08-04 USA)	“Chemical compounds”
774/2005	Wyeth, USA (Priority 16-12-02 USA) Divisional	“Novel compounds for use s anti-aquaretic agents or intermediates thereof”

XXXXXXXXXXXX



GOVERNMENT OF PAKISTAN
THE PATENT OFFICE

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicated their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.



GOVERNMENT OF PAKISTAN
THE PATENT OFFICE

993/2003 Mara-Institut d.o.o. “ The roofing-drainage system for large-span buildings
Croatia “

(Class: E04B, 7/00)

138750

Characterized in that the horizontal channels comprise perforation of cone downwards-extended holes along longitudinal and transversal draining lines.

996/2003 Muhammad Rafique Shakir, “A wide spectrum shampoo composition and a process
Swat, Pakistan for preparation thereof”

(Class: A61K, 7/075)

138751

Comprising the steps of

- i) taking 50 gm of lanolin 25 gm of terpineol hydrate and 150 gm of sodium lauryl sulphate
- ii) taking 100 gm of coconut dieth anolamine and 50 gm of pearliry agent
- iii) mixing 350 of gm aqua of calcium chlorate and 275 gm of aqua barium sulphate
- iv) keeping the mixture of step (iii) without stirring for precipitation for 3 hours, heating after 3 hours,
- v) mixing all together of the above steps in a stainless vessel and stirring for about one hour.

997/2003 Muhammad Rafique Shakir, “A wide spectrum dental paste composition and a
Swat, Pakistan process for preparation thereof”

(Class: A61K, 7/16)

138752

Comprising the steps of



GOVERNMENT OF PAKISTAN
THE PATENT OFFICE

- a) taking 25 gm of terpineol hydrate, 100 gm of lanolin and 150 gm of pearling agent
- b) taking 150 gm of coconut and 100 gm of sodium ether sulphate
- c) mixing 275 gm aqua of calcium chlorate and 175 gm of aqua barium sulphate
- d) keeping the mixture of step 'C' without stirring for precipitation for 3 hours, pouring off, heating after 3 hours at 60°C

1000/2003 Aventis Pharma
Deutschland GmbH,
Germany

“Novel pyridazinone compound as pharmaceuticals and pharmaceutical composition containing them“

(Class: INT.CL: A61K, 31/50, C07D, 237/02, 237/04)

138753

Comprising to pyridiazinone compound to its' process of preparation, to its' pharmaceutical composition containing it, to its' use as anti-inflammatory agent for the treatment of diabetes and cancer.

1001/2003 Aventis Pharma
Deutschland GmbH,
Germany

“Novel pyridazinone compound and pharmaceuticals composition containing it“

(Class: C0D 273/22)

138754

Comprising relates to the compound N-(2-(4-dichlorobenzyl)-3-oxo-6-phenyl-4-yl)-2,3-dihydropyridazine-4-carbonamide to its pharmaceutical use, to its process for preparation.

1003/2003 Pharmacia Corporation,
USA

“ N-terminally monopegylated human growth hormone conjugates and process for their preparation”

(Class : A61K 38/27, A61K 38/08)

138755



GOVERNMENT OF PAKISTAN
THE PATENT OFFICE

Comprises a chemically modified human growth hormone prepared by attaching a polyethylene glycol butyraldehyde moiety to the N-terminal phenylalanine of protein, have a much longer lasting hGH activity than that of the unmodified hGH, enabling reduced dose and scheduling opportunities.

1010/2003 Isolgen Technologies, Inc. “ Treatment of tissue with undifferentiated
USA mesenchymal cells”

(Class: A61K, 35/16)

138756

Comprises autologous passaged undifferentiated mesenchymal cell and autologous, passaged fibroblasts and wherein said composition is substantially free of culture medium serum derived proteins.

750/2005 Pharmacia Corporation, “ N-terminally monopegylated human growth
USA hormone conjugates and process for their preparation”

(Class: A61K, 38/27)

138757

The Comprising relates to the chemically modified human growth hormone (hGH) prepared by attaching a polyethylene glycol butyraldehyde moiety to the N-terminal phenylalanine of the protein.



GOVERNMENT OF PAKISTAN
THE PATENT OFFICE

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55 OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No.137620 dated 9-12-2000, Priority dated 10-12-1999 USA granted to: - The
Dow Chemical Company, a corporation organized and existing under the laws of the State of
Delaware, and having an office and place of business at 2030 Dow Centre, Abbott Road, Midland,
State of Michigan, USA



**GOVERNMENT OF PAKISTAN
THE PATENT OFFICE**

In pursuance of an application received on 1-8-05

The following entry has been made in the register of Patent: -

Equipolymers GmbH of: Berthastrasse 13, 06258 schkopau, Germany as proprietor by virtue of Deed of Assignment dated 11-3-2005 made between The Dow Chemical Company. as Assignor of the ONE PART and Equipolymers GmbH of: Berthastrasse., as Assignee of the OTHER PART.

PROCEEDING UNDER SECTION 42 OF PATENT ORDINANCE, 2000

Any person may give notice of opposition to the amendment proposed in the under mentioned patent No. 137088, dated 28-8-1999 lodging Form 7 of the Patent Rules, 2003 together with the prescribed fee of Rs. 750/- at any time within two months from the date of advertisement in the Gazette , at the Patent Office, 2nd Floor Kandawala Building, M.A. Jinnah Road, Karachi.

2nd Floor, Kandawala Building,
M.A. Jinnah Road, Karachi
URL: <http://www.patent.gov.pk>



GOVERNMENT OF PAKISTAN
THE PATENT OFFICE

Bioengineering Resources, Inc, (a corporation duly incorporated under the laws of the United States of America) of; 1650 Emmaus Road, Fayetteville, Arkansas 72701 USA, and

—
Celanese International Corporation, (a corporation duly incorporated under the laws of the United States of America) of; 1601 West LBJ Freeway, Dallas, Texas 75234 USA.

SEEK TO AMEND THE Specification / claims as above for invention entitled “
IMPROVED MICROBIAL PROCESS, AND IMPROVED SOLVENTS USEFUL IN
THE CONVERSION OF GASES INTO USEFUL PRODUCTS”.

The proposed amendment is desired by way of correction.

The proposed amendment may be inspected in the Patent Office.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55 OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No.138246 dated 17-7-2002, Priority dated 18-7-2001 USA.
granted to: - ENREST R. BODNAR Canadian Citizen, 2 Danrose Crescent Tononto,
Ontario, Canada M3B 3N5.



**GOVERNMENT OF PAKISTAN
THE PATENT OFFICE**

In pursuance of an application received on 12-1-2004.

The following entry has been made in the register of Patent: -

GCG Holdings Ltd., (incorporated in Bahamas), P.O. box N-3933, Nassau, New Providence Island, Bahamas as proprietor by virtue of Deed of Assignment dated 12-6-2003 made between ENREST R. BODNAR as Assignor of the ONE PART and GCG Holdings Ltd, as Assignee of the OTHER PART.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55 OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No.138516 dated 21-4-2003 Granted to:- Horphang Research (UK) Ltd 50 Street, London W1G, 9HQ, United Kingdom.



GOVERNMENT OF PAKISTAN
THE PATENT OFFICE

In pursuance of an application received on 5-3-2005. The following entry has been made in the register of Patent: - Horphag Research (Luxembourg) Holding, S.A, a company Queen Anne duly organized and existing under the laws of LUXEMBOURG having a place of business at 14A, Rue des Bain, L-1212, Luxembourg as proprietor by virtue of Deed of Assignment dated 19th January 2005 made between Horphang Research (UK) Ltd, as Assignor of the ONE PART and Horphag Research (Luxembourg) Holding, S.A, of the Assignee of the OTHER PART.



**GOVERNMENT OF PAKISTAN
THE PATENT OFFICE**

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55 OF THE
PATENTS ORDINANCE 2000**

In the matter of Patent No.137620 dated 9-12-2000 Priority date 10-12-1999 Granted to:- The Dow Chemical Company, a corporation organized and existing under the laws of the State of Delaware, and having an office and place of business at 2030 Dow Centre, Abbott Road, Midland, State of Michigan, USA.

In pursuance of an application received on 1-8-2005

The following entry has been made in the register of Patent: - Equipolymers GmbH of: Berthastrasse 13, 06258 schkopau, Germany as proprietor by virtue of Deed of Assignment dated 11-3-2005 made between The Dow Chemical Company, as Assignor of the ONE PART and Equipolymers GmbH of the Assignee of the OTHER PART.



**GOVERNMENT OF PAKISTAN
THE PATENT OFFICE**

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55 OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No.132950 dated 11-12-1991 Priority Date 12-12-1990 (UK). Granted to:- Imperial Chemical Industries Plc, of Imperial Chemical House, Millbank, London, S.W.1., England a British Company, Manufacturers and Merchants and later on assigned to Zeneca Limited “ the Assignee “ a British company of 15 Stanhope Gate, London W1Y 6LN United Kingdom, whose name was changed to Syngenta Limited, a British company of Syngenta European Regional Centre, Priestley Road, Surrey Research Park, Guildford, Surrey GU2 7YH, United Kingdom.

In pursuance of an application received on 16-8-2005. The following entry has been made in the register of Patent: - Astra Zeneca UK Limited a private Limited company incorporated in the United Kingdom whose Principal place of business is located at 15 Stanhope Gate, London W1Y 6LN United Kingdom as proprietor by virtue of Deed of Assignment dated 27th May, 2004 made between Syngenta Limited., as Assignor of the ONE PART and Astra Zeneca UK Limited the Assignee of the OTHER PARTS.



**GOVERNMENT OF PAKISTAN
THE PATENT OFFICE**

**PROCEEDING UNDER SECTION 54(1), RULE 36(1) FOR CHANGE OF
ADDRESS IN THE REGISTER OF PATENTS.**

In the matter of Patent No.132950 dated 11-12-1991, Priority date 12-12-1990 (UK) granted to:- Imperial Chemical Industries Plc, of Imperial Chemical House, Millbank, London, S.W.1., England a British Company, Manufacturers and Merchants and later on assigned to Zeneca Limited “ the Assignee “ a British company of 15 Stanhope Gate, London W1Y 6LN United Kingdom.

In pursuance of an application received on 12-8-2005. The following entry has been made in the register of Patent: -

The Name of Patentee has been changed to : Syngenta Limited, a British company of Syngenta European Regional Centre, Priestley Road, Surrey Research Park, Guildford, Surrey GU2 7YH, United Kingdom.



**GOVERNMENT OF PAKISTAN
THE PATENT OFFICE**

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55 OF THE
PATENTS ORDINANCE 2000**

In the matter of Patent No.132999 dated 11-12-1991 Priority Date 12-12-1990 (UK). Granted to:- Imperial Chemical Industries Plc, of Imperial Chemical House, Millbank, London, S.W.1., England a British Company, Manufacturers and Merchants and later on assigned to Zeneca Limited “ the Assignee “ a British company of 15 Stanhope Gate, London W1Y 6LN United Kingdom, whose name was changed to Syngenta Limited, a British company of Syngenta European Regional Centre, Priestley Road, Surrey Research Park, Guildford, Surrey GU2 7YH, United Kingdom.

In pursuance of an application received on 16-8-2005. The following entry has been made in the register of Patent: - Astra Zeneca UK Limited a private Limited company incorporated in the United Kingdom whose Principal place of business is located at 15 Stanhope Gate, London W1Y 6LN United Kingdom as proprietor by virtue of Deed of Assignment dated 27th May, 2004 made between Syngenta Limited., as Assignor of the ONE PART and Astra Zeneca UK Limited the Assignee of the OTHER PARTS.



**GOVERNMENT OF PAKISTAN
THE PATENT OFFICE**

**PROCEEDING UNDER SECTION 54(1), RULE 36(1) FOR CHANGE OF
ADDRESS IN THE REGISTER OF PATENTS.**

In the matter of Patent No.132999 dated 11-12-1991, Priority date 12-12-1990 (UK) granted to:- Imperial Chemical Industries Plc, of Imperial Chemical House, Millbank, London, S.W.1., England a British Company, Manufacturers and Merchants and later on assigned to Zeneca Limited “ the Assignee “ a British company of 15 Stanhope Gate, London W1Y 6LN United Kingdom.

In pursuance of an application received on 12-8-2005. The following entry has been made in the register of Patent: -

The Name of Patentee has been changed to : Syngenta Limited, a British company of Syngenta European Regional Centre, Priestley Road, Surrey Research Park, Guildford, Surrey GU2 7YH, United Kingdom.



**GOVERNMENT OF PAKISTAN
THE PATENT OFFICE**

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55 OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No.135155 dated 1123-4-1996 Priority Date 27-4-1995 (UK). Granted to:-Zeneca Limited a British company of 15 Stanhope Gate, London W1Y 6LN United Kingdom and whose name was changed to: Syngenta Limited, a British company of Syngenta European Regional Centre, Priestley Road, Surrey Research Park, Guildford, Surrey GU2 7YH, United Kingdom.

In pursuance of an application received on 16-8-2005. The following entry has been made in the register of Patent: - Astra Zeneca UK Limited a private Limited company incorporated in the United Kingdom whose Principal place of business is located at 15 Stanhope Gate, London W1Y 6LN United Kingdom as proprietor by virtue of Deed of Assignment dated 27th May, 2004 made between Syngenta Limited., as Assignor of the ONE PART and Astra Zeneca UK Limited the Assignee of the OTHER PARTS.



**GOVERNMENT OF PAKISTAN
THE PATENT OFFICE**

**PROCEEDING UNDER SECTION 54(1), RULE 36(1) FOR CHANGE OF
ADDRESS IN THE REGISTER OF PATENTS.**

In the matter of Patent No.135155 dated 23-4-1996, Priority date 27-4-1995 (UK) granted to: -
Zeneca Limited, a British company of 15 Stanhope Gate, London W1Y 6LN United Kingdom.

In pursuance of an application received on 12-8-2005. The following entry has
been made in the register of Patent: -

The Name of Patentee has been changed to : Syngenta Limited, a British company of Syngenta
European Regional Centre, Priestley Road, Surrey Research Park, Guildford, Surrey GU2 7YH,
United Kingdom.



**GOVERNMENT OF PAKISTAN
THE PATENT OFFICE**

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-8 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

138595	Warner-Lambert Company LLC., U.S.A.	613/2003
138596	Wyeth, U.S.A.	648/2003
138597	Cheisi Farmaceutici SPA, Italy	662/2003
138598	GlaxoSmithKline Biologicals S.A. Belgium	673/2003
138599	Otsuka Pharmaceutical Co., Ltd., Japan	877/2003
138600	Wyeth Holdings Corporation, U.S.A.	886/2003
138601	Otsuka Pharmaceutical Co., Ltd., Japan	890/2003



GOVERNMENT OF PAKISTAN
THE PATENT OFFICE

138602

Wyeth,
U.S.A.

899/2003

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Tel: 9215488